Beta-blocker therapy in heart failure: pathophysiology and clinical results.
Georgetown University, Washington, DC, USA.
P E
PE
Carson
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000368:Aged; D017298:Bisoprolol / Q000627:therapeutic use; D002227:Carbazoles / Q000627:therapeutic use; D000077261:Carvedilol; D002986:Clinical Trials as Topic; D015444:Exercise; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D006339:Heart Rate; D006439:Hemodynamics; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008297:Male; D008790:Metoprolol / Q000627:therapeutic use; D008875:Middle Aged; D011412:Propanolamines / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D011788:Quality of Life; D013318:Stroke Volume; D013997:Time Factors; D014665:Vasodilator Agents / Q000627:therapeutic use; D017307:Xamoterol / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D007093:Imidazoles; D011412:Propanolamines; D014665:Vasodilator Agents; D000077261:Carvedilol; D017307:Xamoterol; D011433:Propranolol; C049763:CGP 20712A; C024307:bucindolol; D008790:Metoprolol; D017298:Bisoprolol